| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 1.527 | 2.087 | 2.022 | 3.331 | 2.553 | 3.175 | 6.051 |
| Total Income - EUR | - | - | - | 1.527 | 2.087 | 2.022 | 3.331 | 2.553 | 3.175 | 6.051 |
| Total Expenses - EUR | - | - | - | 1.167 | 1.024 | 1.438 | 1.387 | 1.681 | 1.947 | 2.292 |
| Gross Profit/Loss - EUR | - | - | - | 360 | 1.063 | 584 | 1.944 | 872 | 1.228 | 3.759 |
| Net Profit/Loss - EUR | - | - | - | 314 | 1.001 | 547 | 1.853 | 795 | 1.059 | 3.241 |
| Employees | - | - | - | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
Check the financial reports for the company - Fabron Duomed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | - | - | 476 | 1.476 | 1.964 | 3.779 | 4.555 | 5.706 | 8.882 |
| Inventories | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | 47 | 19 | 597 | 120 | 164 | 182 | 206 |
| Cash | - | - | - | 428 | 1.457 | 1.367 | 3.658 | 4.391 | 5.524 | 8.676 |
| Shareholders Funds | - | - | - | 357 | 1.351 | 1.872 | 3.683 | 4.491 | 5.536 | 8.747 |
| Social Capital | - | - | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | 119 | 126 | 92 | 95 | 65 | 169 | 135 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Fabron Duomed S.r.l.